figshare
Browse
kaup_a_1509818_sm7860.doc (6.57 MB)

Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations

Download (6.57 MB)
Version 3 2019-12-30, 11:22
Version 2 2018-10-12, 14:07
Version 1 2018-08-30, 15:22
journal contribution
posted on 2019-12-30, 11:22 authored by Hongyu Li, Ahrom Ham, Thong Chi Ma, Sheng-Han Kuo, Ellen Kanter, Donghoon Kim, Han Seok Ko, Yi Quan, Sergio Pablo Sardi, Aiqun Li, Ottavio Arancio, Un Jung Kang, David Sulzer, Guomei Tang

Heterozygous mutations in GBA, the gene encoding the lysosomal enzyme glucosylceramidase beta/β-glucocerebrosidase, comprise the most common genetic risk factor for Parkinson disease (PD), but the mechanisms underlying this association remain unclear. Here, we show that in GbaL444P/WT knockin mice, the L444P heterozygous Gba mutation triggers mitochondrial dysfunction by inhibiting autophagy and mitochondrial priming, two steps critical for the selective removal of dysfunctional mitochondria by autophagy, a process known as mitophagy. In SHSY-5Y neuroblastoma cells, the overexpression of L444P GBA impeded mitochondrial priming and autophagy induction when endogenous lysosomal GBA activity remained intact. By contrast, genetic depletion of GBA inhibited lysosomal clearance of autophagic cargo. The link between heterozygous GBA mutations and impaired mitophagy was corroborated in postmortem brain tissue from PD patients carrying heterozygous GBA mutations, where we found increased mitochondrial content, mitochondria oxidative stress and impaired autophagy. Our findings thus suggest a mechanistic basis for mitochondrial dysfunction associated with GBA heterozygous mutations.

Abbreviations: AMBRA1: autophagy/beclin 1 regulator 1; BECN1: beclin 1, autophagy related; BNIP3L/Nix: BCL2/adenovirus E1B interacting protein 3-like; CCCP: carbonyl cyanide 3-chloroyphenylhydrazone; CYCS: cytochrome c, somatic; DNM1L/DRP1: dynamin 1-like; ER: endoplasmic reticulum; GBA: glucosylceramidase beta; GBA-PD: Parkinson disease with heterozygous GBA mutations; GD: Gaucher disease; GFP: green fluorescent protein; LC3B: microtubule-associated protein 1 light chain 3 beta; LC3B-II: lipidated form of microtubule-associated protein 1 light chain 3 beta; MitoGreen: MitoTracker Green; MitoRed: MitoTracker Red; MMP: mitochondrial membrane potential; MTOR: mechanistic target of rapamycin kinase; MYC: MYC proto-oncogene, bHLH transcription factor; NBR1: NBR1, autophagy cargo receptor; Non-GBA-PD: Parkinson disease without GBA mutations; PD: Parkinson disease; PINK1: PTEN induced putative kinase 1; PRKN/PARK2: parkin RBR E3 ubiquitin protein ligase; RFP: red fluorescent protein; ROS: reactive oxygen species; SNCA: synuclein alpha; SQSTM1/p62: sequestosome 1; TIMM23: translocase of inner mitochondrial membrane 23; TOMM20: translocase of outer mitochondrial membrane 20; VDAC1/Porin: voltage dependent anion channel 1; WT: wild type

Funding

This work was supported by grants from National Institute of Mental Health (NIMH) K01 MH096956 (to G.T.), the National Institute of Neurological Disorders and Stroke (NINDS) K08 NS083738 (to S.H.K.), the JPB Foundation and Parkinson’s Disease Foundation (to D.S.), the New York Community Trust and the Michael J. Fox Foundation for Parkinson’s Research (to A.L.), the National Institute on Aging (NIA) AG049402 (to O.A.), the NINDS NS38377 Morris K. Udall Parkinson's Disease Research Center and NINDS NS082205 (to H.K.), the Adrienne Helis Malvin Medical Research Foundation, the Diana Helis Henry Medical Research Foundation and the Foundation’s Parkinson’s Disease Program, H-1, H-2013 (to H.K.).

History

Usage metrics

    Autophagy

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC